Tuberous sclerosis

Tuberous sclerosis (TS) is a hereditary disease characterized by the formation of benign tumors (tubers) in various organs and systems of the body. The pathology is determined by mutations in the TSC1 and TSC2 genes, which control cell growth and division. Changes in these genes lead to the activation of signaling pathways, which causes the development of tumors, often affecting the brain, lungs, heart, kidneys and skin. Tuberous sclerosis can manifest itself as such a symptom as epilepsy, and many other neurological and neuropsychiatric disorders also occur. It is characteristic that the course of the disease can vary significantly from one patient to another, and the severity of manifestations does not always correlate with the results of genetic analysis.

History of the disease and interesting historical facts

Tuberous sclerosis was first described in 1862 by the French physician Emile Dupuytren, who noticed that some patients with skin and neurological manifestations had similar tumors in different organs. In the 1900s, with the growth of medical knowledge about genetics, it was established that TS is a hereditary disease. In 1993 and 1997, scientists identified the TSC1 and TSC2 genes, opening up new horizons in understanding the molecular mechanisms of the disease and laying the foundation for the development of genetic tests. Interestingly, many famous people suffered from tuberous sclerosis, including the legendary composer and pianist Ludwig van Beethoven, highlighting the historical and social significance of this condition.

Epidemiology

Tuberous sclerosis has a prevalence of 1 in 6,000 to 1 in 10,000 live births, making it one of the most common genetic disorders. According to the National Tuberous Sclerosis Foundation, the disease affects people of all races and ethnicities without distinction. Various epidemiological studies show that about 60-70% cases are considered sporadic, while 30-40% have a family history. Statistics indicate that the disease may be underdiagnosed, with incomplete or impaired diagnosis, which often leads to underreporting of cases in neonatal practice.

Genetic predisposition to this disease

The main genetic predisposition to tuberous sclerosis is associated with mutations in two key genes: TSC1 on chromosome 9q34 and TSC2 on chromosome 16p13.3. The TSC1 gene encodes the protein hamartin, and TSC2 encodes the protein tuberin. These proteins form a complex that regulatoryly interacts with the mTOR signaling system, which is responsible for cell growth and metabolism. Genetic studies have identified more than 700 different mutations in TSC1 and TSC2, and their presence can affect cell cloning and metabolism, which ultimately leads to tumor formation. It is important to note that familial cases of the disease may have a high degree of penetrance, while in sporadic cases, mutations often arise de novo.

Risk factors for the development of this disease

Risk factors for tuberous sclerosis are primarily related to genetic mutations that are inherited. In addition, parental age may play a role in the occurrence of sporadic cases. Specific factors may include:

• Having a family history of tuberous sclerosis.
• Age of parents, especially mothers over 35 years old.
• Certain infectious diseases during pregnancy may increase the risk of mutations occurring, although this issue requires further study.

While unproven exogenous factors such as exposure to chemicals or radiation are also under investigation, there is no clear evidence of a link between these factors and an increased risk of developing tuberous sclerosis.

Diagnosis of this disease

Diagnosis of tuberous sclerosis requires a comprehensive approach and may include:

• Clinical assessment based on typical symptoms such as multiple skin manifestations, seizures, intellectual impairment.
• Laboratory tests, including molecular genetic testing to detect mutations in the TSC1 and TSC2 genes.
• Radiological tests such as MRI and CT scans to look for tumors in the central nervous system.
• Ophthalmologic examinations to assess changes in the visual pathways, such as retinal white spots.
• Differential diagnosis with other conditions such as neurofibromatosis, reticular cysts and other syndromes.

Timely and accurate diagnosis is key to prescribing effective therapy and timely monitoring of patients.

Treatment

Treatment of tuberous sclerosis has several goals: reducing the frequency and severity of seizures, treating symptoms associated with tumor formation, and improving the quality of life of patients. There are different approaches to treatment:

• General treatment including rehabilitation and support from social services and psychotherapists.
• Pharmacological treatment, which often begins with antiepileptic drugs if seizures occur.
• Surgical treatment aimed at removing tumors, especially if they are large or have accompanying symptoms.
• Other treatments, such as the use of mTOR inhibitors (eg, cepoglustat) to shrink tumors.

Each method must be individualized based on the clinical picture and general condition of the patient.

List of medications used to treat this disease

The following groups of drugs can be used as part of medical treatment for tuberous sclerosis:

• Antiepileptic drugs: lamotrigine, valproate, levetiracetam.
• mTOR inhibitors: thalidomide, sirolimus.
• Antipsychotic drugs for the treatment of co-occurring behavioral disorders.

It is also strongly recommended to take an individual approach to the choice of treatment, taking into account age and concomitant diseases when choosing medications.

Disease monitoring

Monitoring the condition of patients with tuberous sclerosis includes regular examinations and health monitoring, which allows for the timely detection and correction of complications.

• Monitoring steps may include MRI of the brain every 1-2 years to assess tumor growth.
• The prognosis for the disease often ranges from mild to severe, and many patients can achieve good symptom control if the disease is diagnosed early.
• Complications may include progression of neurological disorders, development of renal failure, and the need for surgery.

Monitoring the dynamics of the disease is important for assessing the quality of life and adaptation of patients.

Age-related features of the disease

Tuberous sclerosis can manifest itself in different age groups, and its course depends on the patient's age at the time of diagnosis.

• Skin manifestations and neuropsychiatric disorders are often seen in newborns and infants and may develop more noticeably with age.
• In children and adolescents, the main problems may be seizures and developmental disorders.
• In adulthood, the incidence of symptoms may increase again due to hormonal changes or underlying conditions.

It is important to take into account age-related characteristics in order to approach treatment and monitoring responsibly.

Questions and Answers

• What is tuberous sclerosis? Tuberous sclerosis is a genetic disorder characterized by the formation of benign tumors in various organs, which can lead to neurological and other systemic disorders.
• What are the main symptoms of tuberous sclerosis? The main symptoms include epileptic seizures, skin changes, mental retardation, and tumors in the kidneys and lungs.
• How to diagnose tuberous sclerosis? Diagnosis includes clinical examination, molecular genetic tests, radiological studies and differential diagnosis with other established diseases.
• What treatments are used for tuberous sclerosis? Treatment may be complex and include pharmacological therapy, surgical treatment and rehabilitation support.
• What is the life expectancy of patients with tuberous sclerosis? The prognosis depends on the severity of the symptoms and the success of treatment; many patients can have a normal life expectancy with adequate therapy.